SynopsisCodesLook ForDiagnostic PearlsDifferential Diagnosis & PitfallsBest TestsManagement PearlsTherapyDrug Reaction DataReferences

View all Images (100)

Pityriasis rubra pilaris
Other Resources UpToDate PubMed

Pityriasis rubra pilaris

Contributors: Teri Greiling MD, PhD, Vivian Wong MD, PhD, Belinda Tan MD, PhD, Susan Burgin MD
Other Resources UpToDate PubMed


This summary discusses pityriasis rubra pilaris in adults. Pityriasis rubra pilaris in children is addressed separately.

Pityriasis rubra pilaris (PRP) is characterized by an acute cutaneous eruption that is usually accompanied by pruritus and pain. There are both acquired and heritable forms. Classic cutaneous lesions include follicular keratotic papules on an erythematous base coalescing to form large, orange-red plaques with characteristic islands of sparing. PRP commonly begins on the scalp and rapidly spreads in a craniocaudal direction, and it has the potential to quickly progress to erythroderma over several weeks' time. Additional features include an orange-red or bright yellow palmoplantar keratoderma. PRP can be classified into 6 clinical types. The clinical types have been suggested to predict response to therapy and disease course, but this has not been validated.
  • Type I (classic adult type, 55% of cases) – Occurs in adults. It is the most common subtype and may clear without therapy within 3-5 years. Relapses are uncommon.
  • Type II (atypical adult type, 5% of cases) – A rare subtype seen in adults. It is characterized by more ichthyosiform (plate-like) scale, increased hair loss, and a chronic and severe course.
  • Type III (classic juvenile type, 10% of cases) – Occurs in children and adolescents. It resembles type I PRP clinically, although erythroderma is less common. Many cases resolve in less than 3 years, but some cases persist longer.
  • Type IV (circumscribed juvenile type, 25% of cases) – Most common subtype in children and adolescents. It is characterized by focal lesions on the extensor surfaces of extremities, over the Achilles, and palmoplantar keratoderma. The clinical course is variable.
  • Type V (atypical juvenile type, 5% of cases) – Typically occurs in the first 2 years of life. It is the most common familial form of PRP and may be associated with CARD14 gene variations, although of note, individuals with CARD14 gene variations (also termed CARD14-associated papulosquamous eruption), may present with features of atypical PRP, classical PRP, or psoriasis.
  • Type VI (HIV-associated type, < 1% of cases) – Occurs in HIV-infected individuals. It may resemble type I PRP or may be part of a follicular occlusion tetrad that includes acne conglobata, hidradenitis suppurativa, and lichen spinulosus.
Symptoms of moderate-to-severe PRP include severe pruritus affecting sleep, burning skin pain, pain from fissures of the hands and feet, and arthralgias. There may be associated ectropion of the eyelids, hair loss, buildup of scale in the ears leading to muffled hearing, and increased rhinorrhea. Erythroderma leads to lack of sweating, difficulty with body temperature regulation, and edema of the legs and arms. These effects may cause difficulty with activities of daily living, including difficulty with fine motor ability and walking, difficulty wearing clothing, and difficulty leaving the home. This results in a strong negative mental health impact including depression, anxiety, embarrassment, and loneliness. Suicidal ideation is common in severe disease and should be assessed carefully.

The etiology of PRP has not been clearly defined. The onset of disease has been associated with vaccines, infection, malignancy, ultraviolet (UV) exposure, and minor skin trauma. Medications have been implicated as causative in a small number of patients, but more studies are needed. Potential culprits include tyrosine kinase inhibitors (ponatinib, imatinib, sorafenib), topical Toll-like receptor 7 (TLR7) agonists (imiquimod), phosphoinositide 3-kinase inhibitors (ofatumumab and idelalisib), antiviral medications (telaprevir, sofosbuvir), and less commonly, programmed cell death protein 1 (PD-1) inhibitors (pembrolizumab), vascular endothelial growth factor (VEGF) inhibitors (bevacizumab), statins (simvastatin), insulin, and angiotensin-converting enzyme (ACE) inhibitors (ramipril). While infliximab can be an effective treatment for PRP, there is one case report of infliximab-induced PRP.

While there are reports of heritable forms, the large majority of PRP cases are acquired and without sex predilection. The incidence of the acquired form occurs in 2 slight peaks: during the first and second decades and during the sixth decade, although it may present at any age.


L44.0 – Pityriasis rubra pilaris

3755001 – Pityriasis rubra pilaris

Look For

Subscription Required

Diagnostic Pearls

Subscription Required

Differential Diagnosis & Pitfalls

To perform a comparison, select diagnoses from the classic differential

Subscription Required

Best Tests

Subscription Required

Management Pearls

Subscription Required


Subscription Required

Drug Reaction Data

Subscription Required


Subscription Required

Last Reviewed:01/01/2023
Last Updated:01/04/2023
Copyright © 2024 VisualDx®. All rights reserved.
Pityriasis rubra pilaris
A medical illustration showing key findings of Pityriasis rubra pilaris : Erythroderma, Fine scaly plaque, Subungual debris, Widespread distribution, Onychauxis
Clinical image of Pityriasis rubra pilaris - imageId=776192. Click to open in gallery.  caption: 'A close-up of an area of normal skin ("island of sparing") surrounded by a deep pink, scaly plaque.'
A close-up of an area of normal skin ("island of sparing") surrounded by a deep pink, scaly plaque.
Copyright © 2024 VisualDx®. All rights reserved.